Incretin Risks Lack Evidence, Says AACE
(MedPage Today) -- There currently is insufficient evidence of a definitive link between incretin diabetes medications and an increased risk of cancer, according to a consensus statement from the American Association of Clinical Endocrinologists. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 22, 2013 Category: Cardiology Source Type: news
The Safety of Incretin Therapy: Are Barriers Beginning to Fall?
The European Medicines Agency declared in July 2013 that there is no evidence that definitively links incretin-based therapy for type 2 diabetes and pancreatitis or pancreatic cancer. Today, August 2, 2013, there are rumors that the US FDA "concurs." (Source: Consultant Live)
Source: Consultant Live - August 3, 2013 Category: Primary Care Source Type: news
FDA Sides With EMA on Incretin Diabetes DrugsFDA Sides With EMA on Incretin Diabetes Drugs
The FDA agrees with the EMA's recent conclusions that firm data lacks support for an increased risk for pancreatic adverse effects with incretin mimetics. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
EMA Finds No Pancreas Risks with Incretins
(MedPage Today) -- The European Medicines Agency has cleared incretin drugs for type 2 diabetes of an association with pancreatic risks. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 29, 2013 Category: Cardiology Source Type: news
EU agency has no new concerns about incretin diabetes drugs
Current data do not confirm recent concerns over an increased risk of pancreatic adverse events with GLP-1-based type 2 diabetes drugs, says the European Medicines Agency. (Source: theHeart.org)
Source: theHeart.org - July 26, 2013 Category: Cardiology Source Type: news
EU Agency Has No New Concerns on Incretin Diabetes Drugs EU Agency Has No New Concerns on Incretin Diabetes Drugs
Current data do not confirm recent concerns over an increased risk for pancreatic adverse events with GLP-1-based type 2 diabetes drugs, says the European Medicines Agency. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the
following statement regarding the conclusion of the European Medicines
Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)
review of GLP-1, or incretin-based, therapies, including sitagliptin.
Language:
English
Contact:
MerckMedia...
Source: Merck.com - Research and Development News - July 26, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Merck's $5.7 Billion Diabetes Franchise Vulnerable
A retrospective analysis published by the BMJ supports previously published findings that diabetic patients taking drugs which target the incretin system to control their blood sugars are at greater risk for developing pancreatic problems, such as acute pancreatitis and pancreatic cancer. Could certain big pharma manufacturers be vulnerable to a price collapse, should European and U.S. regulators ? whom are now actively reviewing data on adverse events ? move to restrict usage or outright remove these therapies from the market due to questionable safety? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 23, 2013 Category: Pharmaceuticals Authors: YCharts Source Type: news
"Breakthrough" Incretin Mimetic Drugs May Cause Pancreatic...
New website offers information about the startling link between incretin mimetics, which are used to treat type two diabetes, and serious illnesses such as renal insufficiency and pancreatic cancer.(PRWeb July 07, 2013)Read the full story at http://www.prweb.com/releases/2013/7/prweb10895062.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 9, 2013 Category: Pharmaceuticals Source Type: news
More Calls for More Research on Incretin Diabetes DrugsMore Calls for More Research on Incretin Diabetes Drugs
The Endocrine Society is the latest organization to call for more research into incretin-based therapies for diabetes and their possible association with pancreatic cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 24, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
ENDO Seconds Call for Incretin Data
SAN FRANCISCO (MedPage Today) -- The Endocrine Society has joined its voice to the recent call for incretin drugmakers to release all patient-level data on their products, the group announced at its annual meeting. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 19, 2013 Category: Cardiology Source Type: news
Society Seconds Call for Incretin Data
SAN FRANCISCO (MedPage Today) -- The Endocrine Society has joined its voice to the recent call for incretin drugmakers to release all patient-level data on their products, the group announced at its annual meeting. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 19, 2013 Category: Cardiology Source Type: news
Incretin Talk Continues at ENDO Meeting
SAN FRANCISCO (MedPage Today) -- As the debate over pancreatic risks with incretin therapies for type 2 diabetes comes to a boil, it's likely to be the topic of much discussion at this year's meeting of the Endocrine Society. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 14, 2013 Category: Cardiology Source Type: news
Pancreatic Cancer and Incretins: No Signal as Yet at NIDDKPancreatic Cancer and Incretins: No Signal as Yet at NIDDK
A definitive answer on whether there is an increased risk of pancreatic cancer with incretin diabetes drugs is still some years away, said dozens of experts at the NIDDK this week. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 14, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
ADA Wants Firms to Disclose Incretin Data
(MedPage Today) -- The American Diabetes Association is calling for makers of incretin therapies to release all of their data on the drugs in an effort to clarify whether they have adverse effects on the pancreas, the group said. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 13, 2013 Category: Cardiology Source Type: news
